Trevi Therapeutics (TRVI) Gains Market Traction After Positive Trial Results
The stock price of Trevi Therapeutics, Inc. (NASDAQ: TRVI) is increasing significantly on the US stock charts due to positive outcomes from the current Phase 2b CORAL study for patients with idiopathic pulmonary fibrosis (IPF) who have a persistent cough. After a sample size re-estimation (SSRE) investigation revealed positive results, TRVI stock gained traction, rising […]
Trevi Therapeutics (TRVI) Gains Market Traction After Positive Trial Results Read More »